Identification of bacteria-selective threonyl-tRNA synthetase substrate inhibitors by structure-based design.
Teng, M., Hilgers, M.T., Cunningham, M.L., Borchardt, A., Locke, J.B., Abraham, S., Haley, G., Kwan, B.P., Hall, C., Hough, G.W., Shaw, K.J., Finn, J.(2013) J Med Chem 56: 1748-1760
- PubMed: 23362938 
- DOI: https://doi.org/10.1021/jm301756m
- Primary Citation of Related Structures:  
4HWO, 4HWP, 4HWR, 4HWS, 4HWT - PubMed Abstract: 
A series of potent and bacteria-selective threonyl-tRNA synthetase (ThrRS) inhibitors have been identified using structure-based drug design. These compounds occupied the substrate binding site of ThrRS and showed excellent binding affinities for all of the bacterial orthologues tested. Some of the compounds displayed greatly improved bacterial selectivity. Key residues responsible for potency and bacteria/human ThrRS selectivity have been identified. Antimicrobial activity has been achieved against wild-type Haemophilus influenzae and efflux-deficient mutants of Escherichia coli and Burkholderia thailandensis.
Organizational Affiliation: 
Medicinal Chemistry, Trius Therapeutics, Inc., 6310 Nancy Ridge Drive, San Diego, California 92121, United States. mteng@triusrx.com